

Sterling



Science

Did you know?

72% of companies

select CDMOs based on their operational, methodological, and therapeutic excellence.¹

The decision to partner with an organisation for outsourced pharmaceutical development and manufacturing requires more than specific services and capabilities. It requires a partner that is dedicated to upholding scientific excellence in everything they do.

At Sterling, scientific excellence is at the heart of our organisation. Our commitment to exceptional science is reflected in our capable team members, world-class facilities, strong partnerships, and comprehensive capabilities, which together support our customers from discovery to commercialisation.

What does **Science** mean to Sterling?



Highly capable team members

Our team is comprised of leading experts in complex and hazardous chemistry, process design, and API development, scale-up, and manufacture. We provide our customers access to our team to enable rich scientific collaboration that drives new levels of programme success.



World-class facilities across the full lifecycle

Our six sites are strategically located, providing our customers with state-of-the-art facilities at every stage of their programme. This includes the best-in-class equipment needed to service their highly specialised requirements and the capacity to support their needs from grams to tonnes throughout the product life cycle.



Strong academic and industry partnerships

Through our Technology and Innovation Programme, we partner with some of the finest academic and technological experts in flow chemistry, chiral chemistry, biocatalysis, and more. By augmenting our own capabilities with the expertise of trailblazers in their fields, we bring true scientific innovation to our customers' programmes.

Bring the Sterling standard for exceptional science to your small molecule programme.

Learn more at
www.sterlingpharmasolutions.com

© 2024 Sterling Pharma Solutions Limited. All rights reserved.

1. <https://www.pharmasolmanac.com/articles/changes-in-the-wind-for-the-cdmo-market>



Cary, North Carolina, US

API development and manufacturing; specialising in early phase development and manufacturing.

Deeside, Wales, UK

ADC research, development and manufacturing bioconjugation services.

Dudley, Northumberland, UK

API development and manufacturing; specialising in hazardous chemistry services rooted in 50+ years' experience.

Germantown, Wisconsin, US

API development and manufacturing; specialising in high potency API (HPAPI) development and manufacturing.

Ringaskiddy, Co. Cork, Ireland

API development and manufacturing; specialising in peptide manufacturing and large scale chromatography.

Newcastle Biosphere, UK

API discovery and early phase chemistry services, including early scale up and analytical services.